Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has issued an announcement.
Shenzhen Hepalink Pharmaceutical Group has clarified details of its proposed final dividend for 2025, confirming a distribution of RMB1.45 per ten ordinary shares, subject to shareholder approval at the annual general meeting on May 22, 2026. The dividend will be paid to H share holders in Hong Kong dollars based on a renminbi exchange rate set in the week before approval, with payment due no later than July 22, 2026.
The company also revised the timetable for determining H share eligibility for the payout, stating that the H share register will be closed from May 29 to June 2, 2026, during which no transfers will be registered. This clarification removes ambiguity from the earlier annual results announcement and gives investors a clear schedule for qualifying for and receiving the final dividend, while confirming that all other disclosed results and plans remain unchanged.
The most recent analyst rating on (HK:9989) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong, primarily engaged in the development and production of heparin-related and other pharmaceutical products for global markets. The group focuses on both domestic and international customers through its H share listing, reflecting an outward-facing capital markets strategy.
As a joint stock company, Hepalink operates under PRC law and maintains a Hong Kong share register for its H share investors, indicating an emphasis on cross-border capital access and investor diversification. Its governance structure includes executive and independent non-executive directors, aligning with Hong Kong listing standards and international corporate governance practices.
Average Trading Volume: 827,619
Technical Sentiment Signal: Sell
Current Market Cap: HK$17B
For an in-depth examination of 9989 stock, go to TipRanks’ Overview page.